Bristol-Myers Squibb Company
NYSE: BMY
$56.80
+$0.58 (+1.0%)
Closing Price on November 18, 2024
BMY Articles
The FDA is routinely criticized for being a poor steward of drug research and pharmaceutical side effects. The agency proved once again why much of the criticism is justified. The FDA today said...
Published:
Last Updated:
Bristol-Myers Squibb Company (NYSE: BMY) is going to completely separate itself from its holdings in Mead Johnson Nutrition Company (NYSE: MJN). The company expects that the split-off will be a...
Published:
Last Updated:
Reuters: The Ohio Attorney General is suing a number of Wall St. firms. Reuters: GM will start to repay part of its debt to the US. Reuters: Citigroup (NYSE:C) will sell Bellsystem to...
Published:
Last Updated:
There are a number of ways to rank brand values. One of the most important is the level at which a brand contributes to the market value of a public company. 24/7 Wall St. asked Corebrand, the brand...
Published:
Last Updated:
These are the top early-bird analyst upgrades and positive research calls which we have seen from Wall Street early this Monday morning: Advanced Micro Devices (NYSE: AMD) Raised to Buy at UBS. Amgen...
Published:
Last Updated:
These are this Friday morning’s top Wall Street analyst upgrades and positive research calls: AK Steel (AKS) Raised to Buy at Deutsche Bank. Bristol-Myers (BMY) Started as Outperform at Wells...
Published:
Last Updated:
Reuters: The best investment for Chinese companies may be the nation’s own 1.3 billion person home market. Reuters: Japan’s Democrats took power. Reuters: Economists say there is no...
Published:
Last Updated:
These are this morning’s top pre-market analyst upgrades, downgrades and initiations from Wall Street early this Friday: Barrick Gold (ABX) Started as Hold at Jefferies. Becton Dickinson (BDX)...
Published:
Last Updated:
These are this morning’s top day trader alerts and most active in price and volume. We have more detailed analysis and data on price and volume with links through to each at VSInvestor.com: JA...
Published:
Diabetes is becoming an epidemic in the U.S. and the Western World. The ties to obesity are often direct, so the potential treatments are often directly tied as well. We did a recent dig down for...
Published:
Last Updated:
Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get a great deal beyond the cancer monoclonal antibody that developed together. The...
Published:
Last Updated:
Reuters: Obama says healthcare reform is essential to the recovery. Reuters: CIT (CIT) bond advisers will push for Chapter 11. Reuters: Democrats will fight with banks on consumer agency....
Published:
Last Updated:
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market....
Published:
Last Updated:
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Published:
Reuters: China must balance growth and reducing greenhouse gases. Reuters: The Supreme Court has delayed Chrysler’s Chapter 11. Reuters: The US will allow 10 banks to repay TARP funds....
Published:
Last Updated: